title: CD133 suppresses neuroblastoma cell differentiation via signal pathway modification.
abstract: CD133 (prominin-1) is a transmembrane glycoprotein expressed on the surface of normal and cancer stem cells (tumor-initiating cells), progenitor cells, rod photoreceptor cells and a variety of epithelial cells. Although CD133 is widely used as a marker of various somatic and putative cancer stem cells, its contribution to the fundamental properties of cancer cells, such as tumorigenesis and differentiation, remains to be elucidated. In the present report, we found that CD133 was expressed in several neuroblastoma (NB) cell lines/tumor samples. Intriguingly, CD133 repressed NB cell differentiation, for example neurite extension and the expression of differentiation marker proteins, and was decreased by several differentiation stimuli, but accelerated cell proliferation, anchorage-independent colony formation and in vivo tumor formation of NB cells. NB cell line and primary tumor-sphere experiments indicated that the molecular mechanism of CD133-related differentiation suppression in NB was in part dependent on neurotrophic receptor RET tyrosine kinase regulation. RET transcription was suppressed by CD133 in NB cells and glial cell line-derived neurotrophic factor treatment failed to induce RET in CD133-expressing cells; RET overexpression rescued CD133-related inhibition of neurite elongation. Of note, CD133-related NB cell differentiation and RET repression were mainly dependent on p38MAPK and PI3K/Akt pathways. Furthermore, CD133 has a function in growth and RET expression in NB cell line- and primary tumor cell-derived tumor spheres. To the best of our knowledge, this is the first report of the function of CD133 in cancer cells and our findings may be applied to improve differentiation induction therapy for NB patients.
authors.affiliation: Division of Biochemistry and Molecular Carcinogenesis,Chiba Cancer Center Research Institute, Chiba, Japan.
authors.forename: H
authors.initials: H
authors.lastname: Takenobu
authors.forename: O
authors.initials: O
authors.lastname: Shimozato
authors.forename: T
authors.initials: T
authors.lastname: Nakamura
authors.forename: H
authors.initials: H
authors.lastname: Ochiai
authors.forename: Y
authors.initials: Y
authors.lastname: Yamaguchi
authors.forename: M
authors.initials: M
authors.lastname: Ohira
authors.forename: A
authors.initials: A
authors.lastname: Nakagawara
authors.forename: T
authors.initials: T
authors.lastname: Kamijo
mesh_terms: D000071916:AC133 Antigen; D000818:Animals; D015703:Antigens, CD / Q000378:metabolism*; D002454:Cell Differentiation / Q000502:physiology; D048708:Cell Growth Processes / Q000502:physiology; D006023:Glycoproteins / Q000378:metabolism*; D057809:HEK293 Cells; D006801:Humans; D051379:Mice; D008819:Mice, Nude; D009447:Neuroblastoma / Q000378:metabolism* / Q000473:pathology*; D010455:Peptides / Q000378:metabolism*; D010766:Phosphorylation; D051096:Proto-Oncogene Proteins c-ret / Q000378:metabolism; D015398:Signal Transduction
chemical_list: D000071916:AC133 Antigen; D015703:Antigens, CD; D006023:Glycoproteins; C000606023:PROM1 protein, human; D010455:Peptides; C000606024:Prom1 protein, mouse; D051096:Proto-Oncogene Proteins c-ret